๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Immunotherapy of cancer: A perspective view

โœ Scribed by R. A. Reisfeld


Publisher
John Wiley and Sons
Year
1988
Tongue
English
Weight
692 KB
Volume
2
Category
Article
ISSN
0887-8013

No coin nor oath required. For personal study only.

โœฆ Synopsis


The current intense interest in cancer immunotherapy is largely based on the fact that progress in the clinical treatment of solid tumors has been less spectacular than anticipated, whereas efforts in basic and preclinical cancer research made some rather remarkable strides during the last two decades. The major challenge that now faces research investigators in cancer imrnuno-Key words: cancer immunotherapy therapy is to determine the functional characteristics of potentially new molecules, important for cancer immunotherapy in both structural and functional terms, to attempt a correlation of their structure with function and to develop, at the basic and preclinical levels, approaches suitable for potential therapy regimens that can be transferred to the clinic for further development.


๐Ÿ“œ SIMILAR VOLUMES


Tumor liberated protein from lung cancer
โœ Giulio Tarro ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 162 KB

## Abstract This review addresses peptide regions of human tumor liberated protein (TLP) complexes with antigenic activity. The review also deals with antibodies reacting with such proteins, to be used for diagnostic and clinical purposes. We identified peptide sequences of the TLP 100โ€‰kDa protein.

Immunotherapy of bladder cancer
โœ Unyime O. Nseyo; Donald L. Lamm ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 48 KB ๐Ÿ‘ 2 views

Intravesical therapy has been used in the management of superficial transitional cell carcinoma (TCC) of the urinary bladder (i.e., Ta, Tl, and carcinoma in situ) with specific objectives which include treating existing/residual tumor, preventing recurrence of tumor, preventing disease progression,

Immunotherapy of metastatic kidney cance
โœ Giancarlo Pizza; Caterina De Vinci; Giuseppe Lo Conte; Paolo Maver; Ennio Dragon ๐Ÿ“‚ Article ๐Ÿ“… 2001 ๐Ÿ› John Wiley and Sons ๐ŸŒ French โš– 337 KB

122 MRCC patients were treated by monthly intralymphatic injections (containing a mean of 573 IL-2 U and 26 ุ‹ 10 6 LAK cells) and i.m. administration of IFN and TF; 71 patients also received a 3-day cycle of monthly IL-2 inhalations with a mean of 998 daily U. MRCC cases not treated by immunotherapy

S 4.6 - Immunotherapy of Cancer
๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 99 KB

## Abstract No Abtract